By InvitationNot Applicable

PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry

United States1,500 participantsStarted 2025-08-14

Plain-language summary

The design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider. Longitudinal data are collected from both subjects and their treating neurology provider during routine clinical encounters using a structured and standardized data collection method. Approximately 1,500 myasthenia gravis subjects with no defined upper limit and 50 clinical neurology sites will be recruited.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Has been diagnosed with myasthenia gravis by a neurologist or a qualified neurology practitioner.
✓. Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment.
✓. Willing and able to provide informed consent.
✓. Willing and able to provide Personally Identifiable Information (full legal name, sex at birth, date of birth, home address zip/postal code and email address or phone Number at a minimum) if required based on registry location and applicable laws and regulations.
✓. In addition, subject must meet at least one of the criteria:
✓. Have started taking a new Enrollment Eligible Medication within 12 months prior to the Enrollment visit. A new medication is a medication that the subject has never taken before.
✓. Is initiating (prescribed or starting) a new Enrollment Eligible Medication at the Enrollment visit. A new medication is a medication that the subject has never taken before.

Exclusion criteria

✕. Is participating or planning to participate in a double-blind clinical trial for a myasthenia gravis drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.

What they're measuring

MG epidemiology

Timeframe: Every 6 months for 10 years

Trial details

NCT IDNCT07217509

SponsorCorEvitas

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2099-12-31

View on ClinicalTrials.gov More Myasthenia Gravis trials